Kamada Ltd., a plasma-derived protein therapeutics company, received an undisclosed additional milestone payment under its supply and distribution agreement with Shire for GLASSIA, Kamada’s intravenous (IV) alpha-1 antitrypsin (AAT). The payment was triggered by Shire achieving a sales milestone for GLASSIA in the U.S. Shire is Kamada’s strategic partner for the exclusive supply and distribution of GLASSIA for all intravenous (IV) indications in the U.S., Canada, Australia, and New Zealand. T...